Mogamulizumab
Mogamulizumab (KW-0761) is a recombinant anti-CCR4 monoclonal antibody (MAb) . Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC) . Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL) [1][2][3].
Product Specifications
CAS Number
[1159266-37-1]
Product Name Alternative
KW-0761
UNSPSC
12352203
Target
CCR
Type
Inhibitory Antibodies
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-anti-virus
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/mogamulizumab.html
Purity
96.9
Solubility
10 mM in DMSO
Smiles
[Mogamulizumab]
Molecular Weight
(146.44 kDa)
References & Citations
[1]Duvic M, et al. Mogamulizumab for the treatment of cutaneous T-cell lymphoma: recent advances and clinical potential. Ther Adv Hematol. 2016 Jun;7 (3) :171-4.|[2]Kanazawa T, et al. Anti-CCR4 monoclonal antibody mogamulizumab for the treatment of EBV-associated T- and NK-cell lymphoproliferative diseases. Clin Cancer Res. 2014 Oct 1;20 (19) :5075-84. |[3]Yamauchi J, et al. Mogamulizumab, an anti-CCR4 antibody, targets human T-lymphotropic virus type 1-infected CD8+ and CD4+ T cells to treat associated myelopathy. J Infect Dis. 2015 Jan 15;211 (2) :238-48. |[4]Maeda S, et al. CCR4 Blockade Depletes Regulatory T Cells and Prolongs Survival in a Canine Model of Bladder Cancer. Cancer Immunol Res. 2019 Jul;7 (7) :1175-1187.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Isoform
CCR4
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
